TenX Biopharma granted Emergent exclusive, worldwide rights to zanolimumab for infectious, cancer and autoimmune indications

TenX Biopharma Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Emergent BioSolutions Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$830.2m on 06/03/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced